Vivimed Labs (NSE:VIVIMEDLAB) Other Current Liabilities: ₹510.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
38 GF Score
Price ₹5.18
GF Value ₹2.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vivimed Labs Other Current Liabilities?

Vivimed Labs NSE:VIVIMEDLAB +0.19% 38 Other Current Liabilities is ₹510.6 Mil as of Mar. 2026. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 38/100 and a GF Value™ of ₹2.46 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Vivimed Labs's other current liabilities for the quarter that ended in Mar. 2026 was ₹510.6 Mil.

Vivimed Labs's quarterly other current liabilities declined from Sep. 2025 (₹497.7 Mil) to Dec. 2025 (₹0.0 Mil) but then increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹510.6 Mil).

Vivimed Labs's annual other current liabilities increased from Mar. 2024 (₹357.9 Mil) to Mar. 2025 (₹449.4 Mil) and increased from Mar. 2025 (₹449.4 Mil) to Mar. 2026 (₹510.6 Mil).

Vivimed Labs Other Current Liabilities Related Terms

Vivimed Labs Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Other Current Liabilities Chart

Vivimed Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.09 355.51 357.93 449.37 510.57

Vivimed Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 449.37 0.00 497.66 0.00 510.57
NSE:VIVIMEDLAB
38GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹510.6 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Other Current Liabilities of ₹510.6 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vivimed Labs.
Is Vivimed Labs' Other Current Liabilities too high?
Vivimed Labs' current Other Current Liabilities is ₹510.6 Mil. Overall, Vivimed Labs has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Other Current Liabilities compare to ZTS?
Vivimed Labs' Other Current Liabilities of ₹510.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vivimed Labs. Vivimed Labs's current Other Current Liabilities is ₹510.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.46, compared to a current price of ₹5.18 — trading 110.6% above its estimated fair value. The current Other Current Liabilities is ₹510.6 Mil. Vivimed Labs' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Other Current Liabilities is ₹510.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.18 is trading 110.6% above its estimated GF Value™ of ₹2.46. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Other Current Liabilities: ₹510.6 Mil
  • GF Value™: ₹2.46 vs. price of ₹5.18 (110.6% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
38GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.18
Price
₹2.46
GF Value